Acetyl Gastric Inhibitory Peptide (human)

Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity[1][2][3].

Research Areas >> Endocrinology

Research Areas >> Metabolic Disease

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Insulin Receptor

Acetyl Gastric Inhibitory Peptide (human) induces cyclic adenosine 3'5' monophosphate (cAMP) production with an EC50 value of 1.9 nM in Chinese hamster lung fibroblast cells transfected with the human GIP receptor[1]. Acetyl Gastric Inhibitory Peptide (human) (10-13-10-8 nM) shows potent effect at stimulating insulin release compared to the native GIP in BRIN-BD11 cells[1]. Acetyl Gastric Inhibitory Peptide (human) improves glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance and reduced insulin secretion[2]. Acetyl Gastric Inhibitory Peptide (human) has metabolic stability and hypoglycemic and insulin modulating activities of two fatty acid derivatized N-terminally acetylated GIP analogs were evaluated in in vitro and in vivo[3].

Acetyl Gastric Inhibitory Peptide (human) (25 nmol/kg; i.p.; single dose) shows resistance to plasma dipeptidylpeptidase IV degradation, resulting in enhanced biological activity and improved antidiabetic potential in vivo[1]. Animal Model: Obese hyperglycaemic (ob/ob) mice[1] Dosage: 25 nmol/kg Administration: Intraperitoneal injection; single dose Result: Lowered individual glucose values at 60 min together with the areas under the curve for glucose compared to native GIP.